SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS Inc.

SCYNEXIS ( ($SCYX) ) has shared an update. On May 19, 2026, SCYNEXIS stockholders approved an amendment to the company’s certificate of incorporati...

Market Cap	$52.18M	P/E Ratio	N/A
52W High	$1.31	52W Low	$0.57
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	51.3%	52W Position	20.4%
Overall Score	49	Value Score	60
Quality Score	31	Technical Score	58

EPS Current Est	$-0.2	EPS Next Est	$-0.1
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SCYX	$0.72	+5.23%	185.48K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SCYX	$0.72	+5.2%	185.48K
3
4
5
6

SCYX

SCYX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get SCYNEXIS Inc. Data in Excel

Get SCYNEXIS Inc. Data in Excel